BEUDAMED
    FDA PMA FDA Class 3 Approved 🇺🇸 United States

    Sensor, Glucose, Implanted, Non-Adjunctive Use

    PMA: P160048 · Supplement: S016 · Decision Feb 10, 2022
    View on FDA
    Classifications
    1
    FEI Numbers
    7
    Registration Numbers
    7

    Basic Information

    Device Name
    Sensor, Glucose, Implanted, Non-Adjunctive Use
    Trade Name
    Eversense® E3 Continuous Glucose Monitoring System
    PMA Number
    P160048
    Supplement Number
    S016
    Device Class
    FDA Class 3
    Product Code
    QHJ
    Generic Name
    Sensor, glucose, implanted, non-adjunctive use
    Medical Specialty
    Unknown
    Advisory Committee
    Clinical Chemistry
    Decision
    Approved
    Decision Code
    APPR
    Decision Date
    February 10, 2022
    Date Received
    September 30, 2020
    Supplement Type
    Panel Track
    Supplement Reason
    Labeling Change - Indications/instructions/shelf life/tradename
    Expedited Review
    N
    Docket Number
    22M-0171

    Advisory Committee Statement

    Approval for the Eversense® E3 Continuous Glucose Monitoring System for expanding the indications for use and modifying the sensor design to allow use for up to 180 days.

    Classifications

    This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

    Product Code Device Name
    QHJ Sensor, Glucose, Implanted, Non-Adjunctive Use